This message was posted by a user wishing to remain anonymous We plan to send out a Dear Dr Letter to notify investigators of a new safety event for our investigational drug. Do we need to submit this read more
This message was posted by a user wishing to remain anonymous Hello, I am working on updating Module 3 sections for an IND as we are beginning Phase 3. This is a clinical-stage biotech and this read more
This message was posted by a user wishing to remain anonymous Fyi, the CFS isn't any kind of exemption. As part of their due diligence they just want to know if you're in good standing with your own read more
This message was posted by a user wishing to remain anonymous Hello Richard, Thanks for your prompt help. Could you please share FDA guidelines to document 'end of life' plan? Do you have any template? read more
This message was posted by a user wishing to remain anonymous Hello, I have never been in this situation and think we are in the clear, but just wanted to see if anyone had a different opinion. read more
View this profile on Instagram RAPS (@regulatoryprofessionals) โข Instagram photos and videos
RAPS (@regulatoryprofessionals) โข Instagram photos and videos
Yemi Ijose Regulatory Affairs Senior Manager GC America Inc. ...
This message was posted by a user wishing to remain anonymous Hello, I have never been in this situation and think we are in the clear, but just wanted to see if anyone had a different opinion. We are a medical device manufacturing company based ...
Hi Everyone Just a reminder we will meet this week at 3 pm to 4 pm on Friday. I will present Chapter 8 of EU, from the 5th edition of the RAPS Study Guide. Join Zoom Meeting https://umaryland.zoom.us/j/96213811970?pwd=V2lQeWowQTAxaDc2U2lpU0h3dVZ4dz09 ...
This message was posted by a user wishing to remain anonymous Hello, I am working on updating Module 3 sections for an IND as we are beginning Phase 3. This is a clinical-stage biotech and this is the DS and DP that will be used in registrational ...
This message was posted by a user wishing to remain anonymous We plan to send out a Dear Dr Letter to notify investigators of a new safety event for our investigational drug. Do we need to submit this Dear Dr. Letter to FDA for review first before sending ...
Regulatory Affairs Professionals Society (RAPS)5635 Fishers Lane, Suite 400Rockville, Maryland 20852
raps@raps.org+1 301 770 2920
JoinMy RAPS DashboardLearn More
About UsTerms of UsePrivacy Policy